Portfolio

Aboleris Pharma is developing new immunomodulators for immune mediated diseases based on its know-how on T cell regulatory function. The vision is to rebalance the ratio of effector (Teff, pro-inflammatory) and regulatory (Treg, anti-inflammatory) functions. Teff /Treg imbalance with a predominance of Teff is at the heart of tissue destruction and organ functional impairment in auto-immune diseases, including inflammatory bowel diseases, rheumatoid arthritis, systemic lupus erythematosus. The company’s lead program is a monoclonal antibody “anti-CD45RC” (ABIS-45RC) to deplete Teff cells and preserve Treg cells.